ChromaDex Releases 3Q10 Financials

IRVINE, Calif.ChromaDex Corp. (OTCBB: CDXC) released the financial results for its third quarter (3Q10), ended Oct. 2, 2010. The company posted revenue of $1.56 million, compared to $1.43 million in the comparable 2009 period; the increase in revenue contrasted with a net loss for 3Q10 of $883,223, compared to a net loss of $177,544 in 3Q09. According to the company, the net loss in the 2010 quarter was attributed to an increase in share-based compensation expenses increased expenses related to marketing and development of its pTeroPure product line; increased legal and accounting expenses; and adoption of a formal investor relations program.

ChromaDex continues to work on implementing its business plan, which included the recent launch of pTeroPure pterostilibene as the next generation resveratrol," said Frank Jaksch, CEO and co-founder of ChromaDex. There are currently 12 products on the market containing pTeroPure pterostilbene and with this increased market adoption we are expecting many more over the next few months, which should give consumers many different options for supplementing with this very promising compound."

ChromaDex has traditionally focused on the development of phytochemical and botanical reference standards and the creation of associated intellectual property. It recently branched out with the commercialization of pTeroPure and holds exclusive worldwide patent rights for the pterostilbene product.